(Q24242729)

5

object named as

A Hillary Steinhart

0 references

author name string

Cynthia H Seow

1

0 references

Anne Marie Griffiths

3

0 references

Anthony R Otley

Cochrane Database of Systematic Reviews

4

0 references

publication date

16 July 2008

0 references

published in

0 references

cites work

Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Quality of life rapidly improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Oral budesonide significantly improves water absorption in patients with ileostomy for Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Association of HLA-DR genotypes and IL-1ra gene polymorphism with treatment failure of budesonide and disease patterns in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Budesonide for maintenance of remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Molecular mechanisms and cellular effects of glucocorticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Inflammatory bowel disease: clinical aspects and established and evolving therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Assessing the quality of randomized trials: reliability of the Jadad scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

A simple index of Crohn's-disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

The effectiveness of budesonide therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Budesonide for induction of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

An index of inflammatory activity in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

Variance imputation for overviews of clinical trials with continuous response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

7 January 2021

Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

7 January 2021

A comparison of budesonide and mesalamine for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

7 January 2021

Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

7 January 2021

Budesonide in the treatment of Crohn's disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

7 January 2021

Treatment of joint pain in Crohn's patients with budesonide controlled ileal release

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

7 January 2021

Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

7 January 2021

A comparison of budesonide with prednisolone for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

7 January 2021

Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

7 January 2021

Oral budesonide in active Crohn's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

7 January 2021

Budesonide and prednisolone suppress peripheral blood natural killer cells in Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB3

7 January 2021